Company: BSTZ
Filing Date: 2025-03-07
Form Type: N-CSR
Source: 0001193125-25-049659
Chunk: 24

Company: BlackRock Science & Technology Term Trust
Filing Date: 2025-03-07
Form: N-CSR
Chunk 24
---
 reinvestment prices. (b) An unmanaged index that features companies involved in medical services or health care in the Russell 3000 ® Index, which includes the largest 3,000 U.S. companies as determined by total market capitalization.

24 2024 BlackRock Annual Report to Shareholders

Trust Summary as of December 31, 2024 (continued) BlackRock Health Sciences Trust (BME)

Performance Returns for the period ended December 31, 2024 were as follows:

|                                                                      | Average Annual Total Returns |         |          |
|                                                                      |                       1 Year | 5 Years | 10 Years |
| Trust at NAV(a)(b)                                                   |                        4.09% |   6.12% |    8.50% |
| Trust at Market Price(a)(b)                                          |                        -0.09 |    3.74 |     6.53 |
| MSCI USA Investable Market Index Health Care Call Overwrite Index(c) |                         1.32 |    5.14 |      N/A |
| Russell 3000®Health Care Index                                       |                         3.48 |    7.18 |     8.81 |

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results. The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance. More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com . The following discussion relates to the Trust’s relative performance based on NAV: What factors influenced performance? At the sector level, security selection in medical devices and supplies, coupled with an underweight in healthcare providers and services, made positive contributions to relative performance. An overweight position in Boston Scientific Corp. was the leading contributor among the Trust’s individual holdings. The company benefited from strong adoption of recently Federal Drug Administration (“FDA”)-approved devices that target high-growth cardiovascular end markets, and it leveraged a robust pipeline of future commercial opportunities. A zero weighting in CVS Health Corp. contributed, as well. The company faced higher than expected costs in its Medicare Advantage business, and it was hurt by broader concerns regarding potential policy changes affecting